Glycomics as prognostic biomarkers of hepatocellular carcinoma: A systematic review.

Autor: Somers N; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Butaye E; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Grossar L; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Pauwels N; Knowledge Center for Health Ghent, Ghent University, Ghent University Hospital, 9000 Ghent, Belgium., Geerts A; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Raevens S; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Lefere S; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium.; Department of Basic and Applied Medical Sciences, Gut-Liver Immunopharmacy Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium., Devisscher L; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium.; Department of Basic and Applied Medical Sciences, Gut-Liver Immunopharmacy Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium., Meuris L; Department of Biochemistry and Microbiology, VIB-UGent Center for Biotechnology, 9000 Ghent, Belgium.; Department of Biochemistry and Microbiology, Ghent University, 9000 Ghent, Belgium., Callewaert N; Department of Biochemistry and Microbiology, VIB-UGent Center for Biotechnology, 9000 Ghent, Belgium.; Department of Biochemistry and Microbiology, Ghent University, 9000 Ghent, Belgium., Vlierberghe HV; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium., Verhelst X; Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.; Hepatology Research Unit, Liver Research Center Ghent, Ghent University, 9000 Ghent, Belgium.
Jazyk: angličtina
Zdroj: Oncology letters [Oncol Lett] 2024 Oct 23; Vol. 29 (1), pp. 24. Date of Electronic Publication: 2024 Oct 23 (Print Publication: 2025).
DOI: 10.3892/ol.2024.14769
Abstrakt: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, which is associated with a low 5-year survival rate. The importance of effective disease monitoring and prognostic evaluation is undeniable. For the present study, a systematic review was performed using extensive searches in Medline, Embase, Web of Science and Scopus up to December 29, 2023. The aim of the present study was to examine whether N-glycomics could predict the risk of developing HCC in adults with chronic liver disease and, if HCC was present, predict overall survival. As a secondary outcome, the prediction capability of HCC recurrence was assessed. After deduplication, 3,904 studies were identified, of which 30 were included. Overall, the median size of the study cohort was 144 patients, with a median follow-up time of 63.6 months. Three studies explored N-glycomics in whole serum, whereas the rest focused on individual glycoproteins, with Mac-2 binding protein glycosylation isomer (M2BPGi) being the most commonly studied. Most articles investigated baseline M2BPGi values as predictors for the development of HCC and demonstrated a median area under the curve of 0.83 with a cut-off index value of 1.8. In conclusion, it was revaled that N-glycan changes exhibit added value in determining patient prognosis in terms of survival, monitoring HCC development and recurrence.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © 2024 Somers et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje